Dengue virus (DENV) is an arbovirus transmitted mainly by two species of mosquitoes: *Aedes aegypti* and *A. albopictus*. This RNA virus belongs to the *Flavivirus* genus of *Flaviviridae* family and infects approximately 390 million persons every year in more than 100 countries. Its genome comprises a ~11kb long single strand positive-sense RNA that encodes a polyprotein precursor that is cleaved by virus and host cell proteases. Thus, this polyprotein yields the structural proteins (E, M and C) as also the non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). There are four different DENV genotypes described (DENV1, DENV2, DENV3 and DENV4). All of them can cause disease in humans. A possible fifth serotype has recently been detected, but it importance as disease agent is not clear.

DENV can cause a wide spectrum of clinical manifestation, ranging from a self-limiting febrile syndrome (dengue fever, DF), severe hemorrhagic syndrome (DHF) and severe shock syndrome (DSS). In 2009, WHO proposed a new criteria for dengue classification according to levels of severity: dengue without warning signs; dengue with warning signs and severe dengue. Abdominal pain, liver enlargement, lethargy, persistent vomiting, fluid accumulation, mucosal
bleeding as also as increasing hematocrit with concomitant decreasing platelets are considered warning signs. Plasma leakage, bleeding, and/or organ failure are considered severe dengue14,5. Neurological complications can also occur in dengue infection6. Severe dengue includes central nervous system (CNS) impairment.

The neurological manifestations in dengue infection are caused mainly by DENV-2 and DENV-3. These serotypes are associated with cases of encephalitis, meningitis and myelitis7,8. However, DENV-1 and DENV-4 are also identified in cases of encephalitis6. Although neurological manifestation is consider uncommon, recent studies showed that it is becoming more frequent in both DF and DHF2,10. About 1-21% of individuals with dengue present neurological abnormalities5-11. When evaluating the suspected cases of CNS infection, dengue was observed in 4-13%12,13. The prevalence of DENV among viral infections in CNS is reported to be 5% and 6% in Vietnam14,15, 15% in India16 and 20% in Thailand17. Our group also demonstrated that in a dengue endemic region (Rio de Janeiro, Brazil), DENV infection was the leading cause of viral encephalitis (47%) and was the etiologic agent of 10% of viral meningitis cases18. Therefore, it seems that neurological complications in dengue infection is becoming increasingly common and is not a rare observation. This fact can be related to the increased concern of the practitioners19. However, it is known that in a secondary dengue infection associated with a different serotype, an antibody dependent enhanced (ADE) mechanism can occur. In those cases, the heterotypic non-neutralizing antibodies interact with dengue virus, favoring the infection of host cell. As consequence, the viral replication is increased, as well the chances of dengue hemorrhagic fever. By hypothesis, the high replication rate may also contribute to the development of neurological disorders (Figure 1)19.

The neuropathogenesis of DENV infection needs to be clarified. The CNS damage can be a result of four distinct mechanisms: (a) metabolic imbalance; (b) hemorrhagic disturbance (thrombocytopenia); (c) post-infectious autoimmune reaction; (d) CNS infection by dengue virus20,21,22. The present narrative review summarizes the advances in the neuropathogenesis studies, in sense of to improve the understanding regarding the neuroinvasiveness, neurotropism and neurovirulence of DENV. Although these themes remain elusive, new knowledge has emerged in recent years.

NEUROINVASION: HOW DENV ACCESS THE NERVOUS SYSTEM

The ability of a microorganism to invade the nervous system is known as neuroinvasion. Hematological seems to be the most important route used by DENV to get into the nervous system. It is preceded by a viremia. The virus can disseminate as a free particle or inside of an infected cell (using a Trojan-horse mechanism of entry)23. A study developed in mice showed that DENV can breakdown the blood-brain barrier (BBB). The BBB is composed by endothelial cells of brain microvessels. During the infection, there is an over-expression of cytokines, that alter the permeability of the endothelium through the disturbance of the tight junctions24,25. In fact, the break of BBB in dengue infection was associated with high levels of plasmatic metalloproteinase 9 (MMP-9)26. MMP digests the basal lamina of neurovascular units, weakening the tight interactions between the endothelial cells and other elements of neurovascular units. Thus, this enzyme facilitate the entry of both free viral particle and infected leukocyte into cerebral tissue27. Moreover, DENV-2-infected monocytes express monocyte chemoattractant protein-1 (MCP-1). In vitro, this protein is able to increase the permeability and disrupt tight junctions of human vascular endothelium cells. In fact, a high expression of MCP-1 was detected in DHF patient’s plasma28. Therefore, DENV is able to enter in the CNS. Another hypothesis is that dengue virus can access the nervous system, crossing the endothelial cells through transcytosis. This entry mechanism has been demonstrated in West Nile virus (WNV) infection29. The ability of DENV to infect endothelial cells allows viral replication and may facilitate the subsequent entry into the brain parenchyma similar to what happens to other flavivirus infections30,31. For hypothesis, it could be the same mechanism that the virus access the cerebrospinal fluid (CSF) cross the blood-CSF barrier. It contain fenestrated vascular endothelial cells on the choroid plexus, which may facilitate the neuroinvasion (Figure 2)32. Moreover, the genetic characterization of DENV-4 obtained in a patient with encephalitis showed 99.99% of similarity between serum and CSF-derived viruses33.

It has been suggested the route of retrograde axonal transport as an alternative neuroinvasive mechanism. An et al.34 showed, using transmission electron microscopy, that DENV is able to penetrate and infect both CNS and peripheral nervous system neurons (motor neurons, axons and ependymal cells) in murine model. In the same study, the authors observed virion-containing vesicles that appeared to be fused to presynapse’s membranes, reinforcing the ability of DENV to use the axonal transport35. Based on this study, the axonal transport could also be used for virus dissemination throughout the nervous system. A negative serum with positive CSF (both collected in same day) DENV detected by polymerase chain reaction (PCR) reinforced this hypothesis36. Although, the presence of virus in CNS may be only the consequence of a passive crossing through the blood-brain and/or blood-CSF barriers. The virus was past in peripheral blood, before crossing the barriers into the brain. Therefore it could not be found in blood anymore.

DENV NEUROTROPISM

There are several evidences that dengue virus is able to infect and replicate in neural cells. This ability is called neurotropism. Viral antigens were detected by immunohistochemistry

Marzia Puccioni-Sohler et al. Neuropathogenesis of dengue infection 699
in human cerebral tissue, DENV RNA was also detected in brain tissue and in CSF of infected individuals. Human and animal neurons, astrocytes, microglia and Purkinje cells can be infected by DENV. Moreover, plexus choroid and endothelial cells were also infected in animal and human studies.

The proteins Hsp70 and Hsp90, seems to form a candidate receptor complex to DENV entry in both human monocytes and neuroblastoma cells. Another possible DENV receptor in neuroblastoma cells is the Mr 65,000 protein. Salazar and colleagues demonstrated that dengue virus can bind to different host cell proteins that are present in both white and grey matter. NS1 dengue antigen was also detected in brain and in CSF of infected individuals. In animal model, previous studies showed that at early stages of the infection, only...
a few virions were present in the cytoplasm of ependymal cells. However, with the progression of the infection, virions were observed in the lumen of the rough endoplasmic reticulum (RER), as also as RER-derived vesicles and the Golgi region of infected neurons. This data demonstrates the DENV neurotropism. Another evidence of CNS infection is the viral detection of DENV-2, -3 and -4 in the CSF in cases of encephalitis, meningitis and myelitis. Additionally, intrathecal synthesis of specific antibodies (calculated by antibody index) was observed in DENV infected patients with myelitis. Therefore, the antibody index for DENV may be used as a marker of myelitis associated with dengue, and it seems to be associated to the pathogenesis of spinal cord disease due to direct viral invasion.

**DENV NEUROVIRULENCE**

Neurovirulence can be defined as the ability of the virus to induce neurologic disease. It is important to note that neurotropism is not a synonym for neurovirulence. However, in some cases, they may be associated. In fact, DENV infection of neuron induced apoptotic cell death in mouse model. The apoptosis may be induced by a cellular stress caused by an accumulation of viral proteins in cell membrane. For example, the neuroadapted BR/90 strain presents some mutations that prevent the maturation of the E protein. So, it results in an abortive virus assembly with an increased accumulation of viral proteins in cell membranes, which, in turn, seems to deflagrate apoptosis. Moreover, the viral infection may trigger the host immune response, which can contribute to neurologic damage. In this context, nitric oxide synthase expression correlates with death in dengue infection in murine model.

In some cases, the virus does not cause neurological disorder, even when infecting the central nervous system. Indeed, in some neuropathological autopsy studies, dengue virus or antigen have been detected in brain tissue without histopathological features of inflammatory reaction. In this context, Bordignon and colleagues, using a mice model, showed that infection with a neurovirulent strain of DENV (FGA/NA) resulted in a higher viral load and progeny in CNS than the infection of the non-neurovirulent strain (FGA/89). Although the FGA/89 can efficiently infect CNS cells, it does not produce neurological disorder neither death of infected animals. In contrast, the neuroadapted virus FGA/NA can replicate more efficiently in CNS, causing extensive inflammatory process characterized by encephalitis and leptomeningitis as observed in histopathological examination. The genetic analysis of these viral strains showed three amino acid substitutions: one in E (structural) protein, and two in NS3 (non-structural) protein.

Interestingly, the genomic sequencing during the neuroadaptation process revealed that the mutations were concomitant with the appearance of signs of encephalitis in mice. Genetic analysis of others neuroadapted strains reveals mutations that mapped to the same viral domain. While mutations in the E protein could enhance the neuropathogenicity of dengue infections by changing the virus binding or entrance into neuronal cells, the mutations in NS3 protein may increase the replicative capacity of DENV, which could explain the higher viral load observed in FGA/NA infection. These data together suggest that both E and NS3 protein are associated with neurovirulence in dengue infection in mice. The identification of molecular signatures associated with neurovirulence of DENV is extremely important as they can serve as molecular markers of neurovirulence. Nevertheless, when evaluating natural human infections, those findings were not observed. Complete genome characterization of DENV-4 did not reveal any of the described mutations associated with neurological strains. The same study observed that the majority mutations were in non-structural proteins encoding genes.

**FROM MOUSE MODEL TO HUMAN INFECTION**

Non-human primates are not suitable models for neurological dengue once they present only a transient viremia, with no clinical signs. Murine model is the most commonly used. Nevertheless, wild type DENV strains are not able to infect nor to induce mice death. So, the researchers have to use immunocompromised animals and/or DENV has to be adapted to this new host. In this adaptation process, which consists of several in vivo or in vitro virus passages, different mutations occur. These mutations take place throughout the genome, but are primarily observed in viral glycoprotein E. In respect to the pathogenesis of neurological dengue, these mutations detected in neuroadapted virus, may cause significant differences between what occurs in human infections to what happens in animal models. Indeed, those mutations were not observed in neurovirulent humans DENV. Moreover, several studies showed that the neurovirulent mutants selected by serial intracerebral passage in mice exhibited significant attenuation for human infection. In the past, this technique was even used to obtain attenuated virus for vaccine development. Therefore, this fact may generate an important bias regarding those studies. Another important issue is that in the majority studies regarding neurovirulence in mouse model, the virus was inoculated through the intra cranial route. As the immune response varies according to the penetration route this can also cause discrepancies between what really happens in humans and what is induced in mice.

In murine model, neuroinfection was observed only in immune or neurological immature mice. However, cases of neurological complications due to dengue infection are observed in adult patients without any sign of immune impairment.
In conclusion, neurological complications in dengue infections are becoming more frequent. Neuroinvasion is not always associated with neurological disease. The demonstration of viral tropism and invasion in human nervous system is well established. Although, the role of viral factors (neurovirulence) still need to be clarified in humans. In addition, the identification of brain damage and viral markers are extremely important to understand the dengue neuropathogenesis. They can also help, in the future, to the establishment of a prognosis, disease control and vaccine development. The intrathecal synthesis of specific antibodies to dengue virus seems to be a good marker of neurovirulence. Genetic analysis, mainly regarding E and NS3 protein, searching for specific mutations, can also be used as a potential neurovirulence marker in dengue infection. The current knowledge concerning neuropathogenesis of dengue virus has been hampered by the lack of an appropriate animal model of disease as also limited autopsy data from fatal human cases. Although the available evidence is still preliminary, it suggests a direction to follow in future studies.

References